Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 2/20 | 0.43 |
| ▸ | PDE5A | O76074 | 17/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL255859 | 0.92 | BUB1 (0.47) | BUB1PDE5ALMNACYP1A2CYP3A4 | |
| SCHEMBL15745570 | 0.89 | BUB1 (0.46) | BUB1PDE5ALMNACYP1A2CYP3A4 | |
| SCHEMBL174945 | 0.88 | BUB1 (0.46) | BUB1PDE5ALMNACYP1A2CYP3A4 | |
| SCHEMBL15745566 | 0.80 | BUB1 (0.50) | BUB1PDE5ALMNACYP1A2CYP3A4 | |
| SCHEMBL256531 | 0.79 | ADORA3 (0.51) | BUB1PDE5ALMNACYP1A2CYP3A4 | |
| SCHEMBL174666 | 0.78 | PDE5A (0.48) | PDE5A | |
| SCHEMBL174613 | 0.78 | PDE5A (0.52) | PDE5A | |
| SCHEMBL175738 | 0.78 | PDE5A (0.52) | PDE5A | |
| SCHEMBL257046 | 0.78 | PDE5A (0.52) | PDE5A | |
| SCHEMBL255864 | 0.78 | PDE5A (0.44) | BUB1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611802-B1 | BICYCLIC AZA-HETEROCYCLES AND THEIR USE | BAYER IP GMBH (DE) | 2016-02-24 | — | — | EP | disclosed |
| US-9096592-B2 | Bicyclic aza heterocycles, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9096592-B2 | Bicyclic aza heterocycles, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20140148433-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| US-20140148433-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| EP-2611802-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028647-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012028647-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148433-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | AADAC, PAICS, TPMT | BUB1 1910/4885PDE5A 152/4885LMNA 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.